This study is testing an experimental drug called ARX788 for people with advanced HER2-positive breast cancer that has spread and has stopped responding to a previous targeted therapy. About 72 participants will receive ARX788 through an IV every three weeks to see if it can shri…
Phase: PHASE2 • Sponsor: Ambrx, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC